Correction: Li et al. Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug–Drug Interaction in Healthy Volunteers. J. Pers. Med. 2021, 11, 457

Error in Table

In the original publication [1], there was a transcription error of the oral midazolam (Table 2) and intravenous (Table S1) area under the curve (AUC) values. The corrected

Table 2. Endogenous and exogenous CYP3A markers in men before and after the repeated administration of ITZ/FKZ/APZ, including ratios of treatment/baseline.

	Baseline	Treatment	Last Washout	Treatment/Baseline (90%CI)	Ratio (90%CI)
ITZ (100 mg od)
1β-OH-DCA/ToDCA	0.15 (0.04–0.50)	0.04 (0.01–0.10)	0.17 (0.05–0.45)	0.25 *** (0.18–0.34)
Oral MDZ CL	126 (46.7–648.8)	37.1 (10.5–79.5)	80.5 (34.8–211.6)	0.30 ** (0.18–0.47)	0.83 (0.43–1.61)
Oral MDZ AUC0-inf	10.8 (2.1–29.1)	36.6 (17.1–129.0)	16.9 (6.4–38.9)	3.40 ** (2.11–5.45)
i.v. MDZ CL	82.9 (48.6–162.1)	36.1 (6.0–111.4)	120 (62.2–262.5)	0.44 * (0.26–0.73)	0.56 (0.35–0.92)
i.v. MDZ AUC0-inf	12.1 (6.17–20.6)	27.7 (9.0–167.4)	9.8 (3.8–16.1)	2.30 * (1.37–3.86)
FKZ (50 mg od)
1β-OH-DCA/ToDCA	0.17 (0.12–0.27)	0.14 (0.07–0.26)	0.18 (0.10–0.42)	0.86 (0.71–1.03)
Oral MDZ CL	59.8 (17.0–135.9)	44.0 (14.8–85.2)	104 (57.6–331.9)	0.74 (0.53–1.02)	1.17 (0.84–1.63
Oral MDZ AUC0-inf	22.7 (10.0–79.6)	30.8 (15.9–91.5)	13 (4.1–23.5)	1.36 (0.98–1.89)
i.v. MDZ CL	80.7 (46.3–276.0)	38.3 (14.4–78.5)	95.1 (46.9–213.4)	0.47 * (0.260–0.866)	1.81 (0.90–3.63)
i.v. MDZ AUC0-inf	12.4 (3.6–21.6)	26.1 (12.7–69.47)	10.5 (4.7–21.3)	2.11 * (1.16–3.85)
APZ (1 mg od)
1β-OH-DCA/ToDCA	0.16 (0.09–0.46)	0.20 (0.10–0.84)	0.18 (0.08–0.32)	1.24 (0.88–1.74)
Oral MDZ CL	59.1 (28.0–220.5)	48.6 (23.7–102.2)	63.6 (38.2–220.5)	0.82 (0.57–1.19)	1.51 (1.02–2.21)
Oral MDZ AUC0-inf	10.56 (6.04–18.49)	8.67 (5.12–14.69)	8.39 (3.81–18.47)	0.80 (0.54–1.18)
i.v. MDZ CL	59.6 (23.3–185.9)	38.1 (21.5–55.5)	53.7 (24.8–81.8)	0.64 (0.400–1.023)	1.94 * (1.16–3.22)
i.v. MDZ AUC0-inf	16.78 (5.38–42.8)	26.25 (18.01–46.44)	18.6 (12.2–40.3)	1.56 (0.98–2.50)

All data are presented as geometric means (range) with 90% confidence intervals (CIs). Ratio: (Treatment_UMR/Baseline_UMR)/(Treatment_{MDZ CL/}Baseline_{MDZ CL}); AUC (h*ng/mL): area under the plasma concentration–time curve; CL (L/h): clearance; DCA: deoxycholic acid; MDZ: midazolam; 1β-OH-DCA: 1β-hydroxy-deoxycholic acid; ToDCA: total deoxycholic acid; od: once daily. * p < 0.05; ** p < 0.01; *** p < 0.001.

and

Table S1. Effect of alprazolam (1 mg) on midazolam and 1′-hydroxymidazolam pharmacokinetics following single dose administration (1.5 mg p.o or 1 mg i.v) in healthy participants (n = 10).

Parameter		Geometric Mean Values (90% CI)		Geometric Mean Ratio (90% CI)	p-Value
		MDZ Alone	MDZ + APZ
MDZ
i.v	AUC0–∞ (ng·h/mL)	16.78 (11.16–25.24)	26.25 (21.18–32.53)	156 (102–240)	0.09
	AUClast (ng·h/mL)	16.64 (11.04–25.07)	24.57 (18.67–32.22)	148 (93–234)	0.12
	Cmax (ng/mL)	25.98 (12.75–52.93)	50.71 (44.81–55.95)	193 (99–377)	0.02
	Tmax (h)	0.29 (0.22–0.37)	0.30 (0.24–0.37)
	T1/2 (h)	2.06 (1.62–2.61)	3.73 (1.80–7.73)
	CL (L/h)	59.88 (39.62–89.50)	38.09 (30.73–47.20)
p.o.	AUC0–∞ (ng·h/mL)	10.56 (6.04–18.49)	8.67 (5.12–14.69)	80 (54–118)	0.30
	AUClast (ng·h/mL)	10.43 (7.84–13.86)	10.85 (3.92–6.45)	104 (71–153)	0.23
	Cmax (ng/mL)	4.13 (3.33–5.11)	5.03 (3.92–6.45)	122 (89–166)	0.07
	Tmax (h)	0.76 (0.60–0.95)	1.03 (0.81–1.31)
	T1/2 (h)	1.63 (1.01–2.62)	1.47 (1.11–1.95)
	CL (L/h)	137.34 (101–186)	136.46 (101–184)
1′-OH-MDZ
i.v	AUC0–∞ (ng·h/mL)	4.49 (2.12–9.50)	2.25 (1.07–4.72)	49 (18–100)	0.03
	AUClast (ng·h/mL)	2.54 (1.49–4.35)	1.81 (0.84–3.86)	71 (28–179)	0.26
	Cmax (ng/mL)	1.24 (1.02–1.50)	1.06 (0.88–1.27)	85 (67–109)	0.09
	Tmax (h)	0.81 (0.65–1.10)	0.77 (0.66–0.89)
	T1/2 (h)	2.21 (0.89–5.49)	1.15 (0.61–2.18)
	CL (L/h)	-	-
p.o.	AUC0–∞ (ng·h/mL)	10.56 (6.77–16.48)	9.19 (5.76–14.69)	87 (48–157)	0.16
	AUClast (ng·h/mL)	8.23 (6.15–11.02)	4.90 (3.53–6.80)	60 (40–89)	0.01
	Cmax (ng/mL)	2.60 (2.13–3.18)	1.70 (1.44–2.01)	65 (52–83)	0.01
	Tmax (h)	0.77 (0.65–0.91)	1.03 (0.84–1.27)
	T1/2 (h)	2.54 (1.26–5.09)	4.83 (2.41–9.66)
	CL (L/h)	-	-

MDZ, midazolam; APZ, alprazolam; CI, confidence interval; AUCt0–tlast - area under the plasma concentration–time curve from time zero to the last sampled time point; AUCinf, AUC from time zero to infinity; Cmax, peak plasma concentration of the drug; Tmax, time needed to achieve Cmax.

appear below.

Updating Conflicts of Interest Statement

In the original publication [1], the Conflict of Interest declaration did not fully reflect the required disclosure of conflicts of interest. The corrected Conflict of Interest appear below.

Conflicts of Interest: Authors X.-Q.L. and T.B.A. were employed by the company AstraZeneca. Authors C.M. and R.S.T. were employed by the African Institute of Biomedical Science and Technology (AiBST). The authors declare that this study received funding from AstraZeneca and institutional infrastructure and operations support from AiBST. The funder had the following involvement with the study: the conception & design, the analysis, interpretation of data, the writing of this article.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.